MedTrace Logo

Enhancing the Natriuretic Peptide System in HFpEF

NCT05279742 · Status: ENROLLING_BY_INVITATION · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-10-09

No results posted yet for this study

Summary

The purpose of this study is to look at the differences in how individuals with heart failure with preserved ejection fraction in the presence of chronic kidney disease (HFpEF-CKD) and exercise induced dyspnea without objective findings of fluid retention (HFpEF-EI) bodies function using drugs Sacubatril/Valsartan (Entresto) and MANP.

Conditions

Interventions

DRUG

MANP

Single subcutaneous injection 5 µg/Kg

DRUG

Sacubitril/Valsartan

Oral single dose 97/103 mg

DRUG

Oral Placebo

Oral single dose that contains no active ingredient

DRUG

Injection Placebo

Single subcutaneous injection that contains no active ingredient

Sponsors & Collaborators

  • Horng Chen

    lead OTHER

Principal Investigators

  • Paul M McKie · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-04
Primary Completion
2027-04-30
Completion
2027-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05279742 on ClinicalTrials.gov